Blade Therapeutics develops novel therapies aimed at modifying the pathobiology and halting progression of fibrotic diseases. The company exploits novel target biology based on research from the laboratory of Harry (Hal) Dietz at Johns Hopkins University. Blade is led by CEO Wendye Robbins, M.D. The company intends to use the new funding to advance selection and development of lead molecules. In conjunction with the financing, representatives from investors joined Blade’s board to support development efforts. The company is headquartered in South San Francisco, CA.

Total raised

$45M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2016